Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials

医学 内科学 鼻咽癌 不利影响 安慰剂 中止 肿瘤科 吉西他滨 化疗 放射治疗 病理 替代医学
作者
Hong Sun,Fengjiao Bu,Ling Li,Xiuwen Zhang,Xiu Lan Xin,Jingchao Yan,Taomin Huang
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:58 (4): 349-359 被引量:4
标识
DOI:10.1177/10600280231188171
摘要

BACKGROUND: Different clinical trials for recurrent or metastatic nasopharyngeal carcinoma have studied different combinations of immuno-oncology in first-line treatment, but the optimal choice has not been determined. OBJECTIVE: To systematically examine and compare the efficacy and safety of different immune checkpoint inhibitors (ICIs) combined with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma. METHODS: Several electronic databases were systematically searched up to February 2023. Articles meeting the inclusion criteria were included. RESULTS: Three RCTs were eligible in the study. Compared with placebo plus gemcitabine-cisplatin (GP), toripalimab plus GP (HR = 0.59, 95% CI: 0.37-0.95) was significantly associated with a better OS. Tislelizumab plus GP generated best progression-free survival (PFS) benefit (HR = 0.50, 95% CI: 0.37-0.67), greatest improvement in 1-year PFS rate (RR = 3.00, 95% CI: 1.84-5.22), and objective response rate (ORR) (RR = 1.26, 95% CI: 1.04-1.53) over the placebo plus GP. Furthermore, tislelizumab plus GP appeared to be safer than toripalimab plus GP and camrelizumab plus GP in terms of adverse events (AEs)-grade ≥3, treatment-related AEs (TRAEs)-grade ≥3, serious AEs (SAEs), treatment-related SAEs (TRSAEs), and AEs leading to discontinuation of treatment. CONCLUSION AND RELEVANCE: In recurrent or metastatic nasopharyngeal carcinoma, programmed death 1 (PD-1) inhibitors plus GP as first-line treatment have better survival outcomes than placebo plus GP with comparable toxicity. Toripalimab plus GP shows the best OS benefit over placebo plus GP, while tislelizumab plus GP generates the best PFS, 1-year PFS rate, ORR, and safety. Tislelizumab plus GP could be the best choice among the ICIs combined with chemotherapy regimens as first-line treatment in recurrent or metastatic nasopharyngeal carcinoma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
min完成签到,获得积分10
1秒前
追寻一一完成签到 ,获得积分10
1秒前
2秒前
2秒前
2秒前
2秒前
Li发布了新的文献求助10
3秒前
4秒前
5秒前
Ming发布了新的文献求助10
6秒前
DZS完成签到 ,获得积分10
6秒前
6秒前
积极凌兰完成签到 ,获得积分10
6秒前
郭娅楠发布了新的文献求助10
7秒前
orixero的应助被包包糖在摸鱼采纳,获得10
8秒前
leilei发布了新的文献求助10
9秒前
Zllu完成签到,获得积分10
10秒前
Lucas的应助被科研通管家采纳,获得10
10秒前
情怀的应助被科研通管家采纳,获得10
10秒前
初景的应助被科研通管家采纳,获得20
10秒前
Orange的应助被科研通管家采纳,获得10
10秒前
10秒前
wanci的应助被jls采纳,获得10
10秒前
华仔的应助被科研通管家采纳,获得30
10秒前
天天快乐的应助被科研通管家采纳,获得10
11秒前
彭于晏的应助被科研通管家采纳,获得10
11秒前
Hello的应助被科研通管家采纳,获得10
11秒前
berg发布了新的文献求助10
11秒前
FashionBoy的应助被王肄博采纳,获得10
11秒前
11秒前
shiyin完成签到 ,获得积分10
12秒前
13秒前
乐观的凝梦完成签到,获得积分10
14秒前
黄紫红完成签到 ,获得积分10
14秒前
灵兰发布了新的文献求助10
14秒前
无语的香薇完成签到 ,获得积分10
15秒前
聪慧的跳跳糖完成签到,获得积分10
15秒前
火星上的芳芳完成签到,获得积分10
16秒前
lyz完成签到,获得积分10
17秒前
Zhudongyu发布了新的文献求助30
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186676
求助须知:如何正确求助?哪些是违规求助? 9574945
关于积分的说明 21839037
捐赠科研通 7784275
什么是DOI,文献DOI怎么找? 3434808
关于科研通互助平台的介绍 2559187
邀请新用户注册赠送积分活动 2481611